Literature DB >> 18025891

Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.

Laura J Waters1, Sundhiya Mandalia, Brian Gazzard, Mark Nelson.   

Abstract

Suspected hypersensitivity is the main reason for the early discontinuation of abacavir. After the observation that the risk of hypersensitivity correlated with ethnicity, the presence of the HLA allele B5701 was found to be the strongest retrospective predictor of hypersensitivity. Two prospective cohorts have since demonstrated a significant reduction in abacavir hypersensitivity rates with the use of prospective human leukocyte antigen screening. We describe our experience of prospective HLA-B5701 testing and the impact on rates of abacavir hypersensitivity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18025891     DOI: 10.1097/QAD.0b013e328273bc07

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  24 in total

1.  Successes achieved and challenges ahead in translating biomarkers into clinical applications.

Authors:  Greg Tesch; Shashi Amur; John T Schousboe; Jeffrey N Siegel; Lawrence J Lesko; Jane P F Bai
Journal:  AAPS J       Date:  2010-03-16       Impact factor: 4.009

Review 2.  Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.

Authors:  M A Martin; T E Klein; B J Dong; M Pirmohamed; D W Haas; D L Kroetz
Journal:  Clin Pharmacol Ther       Date:  2012-02-29       Impact factor: 6.875

Review 3.  Hypersensitivity reactions to HIV therapy.

Authors:  Mas Chaponda; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

4.  Severe skin rash associated with atazanavir.

Authors:  Andrew Walkty; Dick Smith; Bernie Lopko; Ken Kasper
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

5.  Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.

Authors:  Edward D Esplin; Ling Oei; Michael P Snyder
Journal:  Pharmacogenomics       Date:  2014-11       Impact factor: 2.533

6.  PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

Authors:  Julia M Barbarino; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2015-04       Impact factor: 2.089

Review 7.  Successful translation of pharmacogenetics into the clinic: the abacavir example.

Authors:  Elizabeth Phillips; Simon Mallal
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

8.  Abacavir-induced fulminant hepatic failure in a HIV/HCV co-infected patient.

Authors:  Christopher Haas; Mary Rodriguez Ziccardi; Jody Borgman
Journal:  BMJ Case Rep       Date:  2015-12-15

9.  PharmGKB summary: abacavir pathway.

Authors:  Julia M Barbarino; Deanna L Kroetz; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-05       Impact factor: 2.089

Review 10.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Authors:  Patricio Godoy; Nicola J Hewitt; Ute Albrecht; Melvin E Andersen; Nariman Ansari; Sudin Bhattacharya; Johannes Georg Bode; Jennifer Bolleyn; Christoph Borner; Jan Böttger; Albert Braeuning; Robert A Budinsky; Britta Burkhardt; Neil R Cameron; Giovanni Camussi; Chong-Su Cho; Yun-Jaie Choi; J Craig Rowlands; Uta Dahmen; Georg Damm; Olaf Dirsch; María Teresa Donato; Jian Dong; Steven Dooley; Dirk Drasdo; Rowena Eakins; Karine Sá Ferreira; Valentina Fonsato; Joanna Fraczek; Rolf Gebhardt; Andrew Gibson; Matthias Glanemann; Chris E P Goldring; María José Gómez-Lechón; Geny M M Groothuis; Lena Gustavsson; Christelle Guyot; David Hallifax; Seddik Hammad; Adam Hayward; Dieter Häussinger; Claus Hellerbrand; Philip Hewitt; Stefan Hoehme; Hermann-Georg Holzhütter; J Brian Houston; Jens Hrach; Kiyomi Ito; Hartmut Jaeschke; Verena Keitel; Jens M Kelm; B Kevin Park; Claus Kordes; Gerd A Kullak-Ublick; Edward L LeCluyse; Peng Lu; Jennifer Luebke-Wheeler; Anna Lutz; Daniel J Maltman; Madlen Matz-Soja; Patrick McMullen; Irmgard Merfort; Simon Messner; Christoph Meyer; Jessica Mwinyi; Dean J Naisbitt; Andreas K Nussler; Peter Olinga; Francesco Pampaloni; Jingbo Pi; Linda Pluta; Stefan A Przyborski; Anup Ramachandran; Vera Rogiers; Cliff Rowe; Celine Schelcher; Kathrin Schmich; Michael Schwarz; Bijay Singh; Ernst H K Stelzer; Bruno Stieger; Regina Stöber; Yuichi Sugiyama; Ciro Tetta; Wolfgang E Thasler; Tamara Vanhaecke; Mathieu Vinken; Thomas S Weiss; Agata Widera; Courtney G Woods; Jinghai James Xu; Kathy M Yarborough; Jan G Hengstler
Journal:  Arch Toxicol       Date:  2013-08-23       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.